NORTH WEST LUNG CENTRE
Promoting and assisting with the funding of research into lung disease in the North West of England
Objects
1) TO PROMOTE RESEARCH INTO THE COURSES AND TREATMENT OF HUMAN DISEASES AND TO DISSEMINATE THE SAVE TO THE PUBLIC AND DISTRIBUTION.2) TO ENGAGE IN RESEARCH AND DEVELOPMENT OF RESPIRATORY MEDICINES AND GENERAL MEDICINES FOR USE IN CONJUCTION WITH THE TREATMENT REFERRED TO IN 1) ABOVE3) TO PROMOTE THE HEALTH AND WELL BEING OF PATIENTS WITH RESPIRATORY OR RELATED DISEASES
Financial health, per its FY2025 accounts
The accounts state that the group's unrestricted reserves totalled £129,938,522, a significant increase from the previous year's £36,234,558, driven largely by a £90.1 million gain on the revaluation of investments in subsidiary companies. The trustees report that the charity maintains sufficient reserves to support current research, noting that the approach to reserve funds will be tailored to the post-acquisition strategy following the sale of its subsidiaries. The independent auditors confirmed that the financial statements are prepared on a going concern basis with no material uncertainties identified.
What the accounts disclose
“It is the trustee’s policy to maintain sufficient reserves to enable the Charity to continue to support current research.” — page 7
“An honorarium of £6,000 was payable to trustee J Alcock in the year (2024 £Nil).” — page 27
“During the year, total dividends of £1,147,791 (2024 - £495,788) were paid to the directors of Medicines Evaluation Unit Limited and CRO Solutions Limited.” — page 36
“A Pickering Fellowship award was granted to the Manchester University NHS Foundation Trust in 2024 in respect of funding salary support for Trustee Dr H Badri. The initial grant amounted to £63,000, with an additional amount of £3,891 awarded during the year. A total of £33,543 was paid during the current year.” — page 36
“During the year, total dividends of £1,147,791 (2024 - £495,788) were paid to the directors of Medicines Evaluation Unit Limited and CRO Solutions Limited.” — page 36
“A Pickering Fellowship award was granted to the Manchester University NHS Foundation Trust in 2024 in respect of funding salary support for Trustee Dr H Badri. The initial grant amounted to £63,000, with an additional amount of £3,891 awarded during the year. A total of £33,543 was paid during the current year.” — page 36
“The group financial statements consolidate the financial statements of the charitable company and its subsidiaries, Medicines Evaluation Unit Limited and CRO Solutions Limited on a line by line basis.” — page 19
Policies the charity declares
- Bullying and harassment policy and procedures
- Campaigns and political activity policy and procedures
- Complaints policy and procedures
- Conflicting interests
- Engaging external speakers at charity events policy and procedures
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Internal risk management policy and procedures
- Investing charity funds policy and procedures
- Investment
- Risk management
- Safeguarding policy and procedures
- Serious incident reporting policy and procedures
- Social media policy and procedures
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
From the charity’s annual return (Part A, self-declared)
Self-declared on the annual return for the financial year ending 31/03/2025
- Trustee benefits, answered Yes to: any trustee benefit; other trustee benefit
- Has a trading subsidiary
- Grant-making is its main activity
Self-declared on the annual return for the financial year ending 31/03/2024
- Trustee benefits, answered Yes to: any trustee benefit; other trustee benefit
- Has a trading subsidiary
- Grant-making is its main activity
Self-declared on the annual return for the financial year ending 31/03/2023
- Trustee benefits, answered Yes to: any trustee benefit; payments to trustees for services to the charity; other trustee benefit
- Has a trading subsidiary
- Grant-making is its main activity
Annual return filing dates (Charity Commission record)
Of its last 5 annual returns with a recorded received date, 3 were received after the due date: year ending 31/03/2025 (received 30/03/2026, 58 days after the 31/01/2026 due date); year ending 31/03/2022 (received 18/07/2023, 168 days after the 31/01/2023 due date); year ending 31/03/2021 (received 22/07/2022, 172 days after the 31/01/2022 due date).
Corporate structure
- Trading subsidiary: MEDICINES EVALUATION UNIT LIMITED Companies House 03779957 · Financial health read from its filings
- Registered company of the charity Companies House 03936652
- Trading subsidiary: CRO SOLUTIONS LIMITED Companies House 09157193
- Profit/loss before tax: £2.6m
- Equity: £975
- Average employees: 1.6
- Profit/loss before tax: £700k
- Equity: £1k
- Average employees: 0.16
- Turnover: £18.2m
- Profit before tax: £6.0m
- Turnover: £7.2m
- Profit before tax: £512k
- Sales of £795,719 and purchases of £4,964,812 with Medicines Evaluation Unit Limited.
Company officers (Companies House)
- SINGH, Sukh Dave, Professor on trustee list
- BOOTON, Richard, Professor on trustee list
- PIKE, Malcolm John on trustee list
- CLARKE, Alan on trustee list
- HEATLEY, Timothy Graham on trustee list
- BAILEY, Richard Charles on trustee list
- WOODCOCK, Ashley Arthur, Professor on trustee list
- BROWN, Louise Ann, Dr on trustee list
- BADRI, Huda, Dr on trustee list
- VESTBO, Jorgen, Professor on trustee list
- MURRAY, Clare Suzanne, Dr on trustee list
- JONES, Andrew Mark, Dr on trustee list
- MURRAY, Clare Suzanne, Professor
Property (HM Land Registry)
Structured financials (annual return, FY ending 31/03/2025)
Trustees
- Alan Clarke
- Malcolm Pike
- Professor Andrew Mark Jones
- Professor Ashley Woodcock
- Professor Clare Suzanne Murray
- Professor Jorgen Vestbo
- Professor Sukh Dave Singh
- RICHARD BAILEY
- Timothy Graham Heatley
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/03/2025 | £20.9m | £16.0m |
| 31/03/2024 | £19.6m | £13.0m |
| 31/03/2023 | £19.0m | £15.1m |
| 31/03/2022 | £17.5m | £13.1m |
| 31/03/2021 | £15.9m | £12.5m |
Common questions
Is NORTH WEST LUNG CENTRE financially healthy?
Per its FY2025 accounts: The accounts state that the group's unrestricted reserves totalled £129,938,522, a significant increase from the previous year's £36,234,558, driven largely by a £90.1 million gain on the revaluation of investments in subsidiary companies. The trustees report that the charity maintains sufficient reserves to support current research, noting that the approach to reserve funds will be tailored to the post-acquisition strategy following the sale of its subsidiaries. The independent auditors confirmed that the financial statements are prepared on a going concern basis with no material uncertainties identified. Its FY2025 accounts were audited by Mitchell Charlesworth (Audit) Limited.
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| ASSOCIATION OF NHS CHARITIES | 1 | £85k |
| THE RCN FOUNDATION | 1 | £30k |
| KUSUMA TRUST UK | 1 | £10k |
Charities like this
- THE WEST FOUNDATION
- NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH CCR)
- LONDON NORTH WEST HEALTHCARE CHARITABLE FUND
- WYTHENSHAWE HOSPITAL TRANSPLANT FUND
- MULTIPLE SCLEROSIS THERAPY CENTRE SOUTH WEST LIMITED
- WESSEX CARDIAC TRUST
Side by side with its peers
| Charity | Income | Top pay band | Staff >£60k | Reserves vs policy | Fundraising cost | Going concern |
|---|---|---|---|---|---|---|
| NORTH WEST LUNG CENTRE | £20.9m | — | — | unclear | — | no doubt |
| THE WEST FOUNDATION | £77k | — | 0 | above | — | no doubt |
| NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH CCR) | £2.3m | — | — | above | — | no doubt |
| LONDON NORTH WEST HEALTHCARE CHARITABLE FUND | £769k | — | 3 | above | — | no doubt |
| WYTHENSHAWE HOSPITAL TRANSPLANT FUND | £218k | — | 0 | unclear | — | no doubt |
| MULTIPLE SCLEROSIS THERAPY CENTRE SOUTH WEST LIMITED | £325k | — | 0 | above | — | no doubt |